Thank you. I've been a health care practitioner (retired) in pediatrics and a microbiologist and have had multiple friends, patients, and family members afflicted by many forms of cancer (just lost the 9 year old son of a friend die).. sat through radiation treatment sessions, chemo infusions, watched a friend involved in a clinical trial for now a marketed product that extended his "death sentence" window of 4-6 weeks to almost a year, and sat up all night with friends sick from treatment. People do so many things to themselves and then expect a pill to remedy the problem. There is a big picture here, and if one is going to invest in biotech stocks it does help to comprehend the issues, market size, and some of the science.
Chemotherapy treatment is unrelated to advertising. The uses will be determined by oncologists both on and off label. In many ways this product's research is still in its infancy and its eventual total market a mystery. That said, FDA approval opens doors in every direction, and whether EXEL takes it to its goal or the company is bought out remains another mystery. Unlike many other medical interventions patients needing this treatment will die of their disease- and many will die soon. Diabetes, heart disease, and the millions of other maladies out there are not necessarily lethal in the same category as cancer, so when you look at "side-effects" those need to be put in perspective. I'm not saying people don't die from complications of diabetes or heart disease and often simple life style adjustments can affect one's life expectancy, but these cancers are deadly and failure to treat fast and with hard hitting drugs is a death sentence.. Different sand-boxes, different rules.This story is far from over.
Sentiment: Strong Buy
We should all also remember that there have been phase 1 trials in other forms of CA, and with approval the opportunity and incentive to advance to phase 2 trials are more likely to accelerate. It also can begin to be used as an adjunct treatment in other trials. Solid tumors, glioblastoma, NSC lung cancer etc and partners come knocking. Oral formulations are an asset.
The primary endpoint is 17 months which from the completion of enrollment in 11/14 would be just about now for all patients. Have incomplete results is less compelling, so my guess is the FDA is waiting for the final numbers. Often that's six months after completion - which puts it to October, but perhaps this will be faster. There are no results posted on clinical trials, and preparing the data for submission takes time as does putting it on the FDA's calendar. They want the data complete.
It might be more effective to define your reasoning for this statement. If you are going to shout, at least provide evidence, otherwise you might be mistaken for a pumper/dumper.
Sentiment: Strong Buy
I would add generous to that assessment. Apparently of the $102 million in Trump's charitable (I use that word loosely ) donations $0 of that was cash..all hotel stays and rounds of golf to auctions etc. I thought a definition of real charity also has the hook that the giver can or does feel some impact on personal wealth. I know people who make poverty level wages and make cash donations.
I am in a similar situation. I invest for the family and a couple of friends. Managed accounts for my mother before she passed away, kept her living very comfortably, inherited from her (along with my brother) and am now retired at 60 and my brother will also be retiring in a year thanks to that growth and each of our own savings (and my long term management and yea paying for advice digs into profits big time). I kept about 5-6% in high spec but diversified and very well researched, another 15% or so in what I see as niche/growth/one of a kind and the rest kind of tiered. I like biotech since my background is microbiology and healthcare so I can read the science and research and enjoy that part of it since I understand and appreciate from both the healthcare need and scientific perspective. If you haven't discovered clinical trials website, give it a try. It helps you investigate where companies are testing their products and keys you in to real time frames for results etc.
and one more..that 50 share bid may have been my son! He is now beginning to build a portfolio and is starting with $4K. I believe this was one I mentioned he should look at - he doesn't know how many shares are still in his trust- but he is a penny pincher and wants to save and grow his money wisely.
I completely agree with the last statement. I have a bunch, never sold any, started in at $2.01 and bought between that and $3.55. I do believe a healthcare company with an established international distribution network and the ability to mass produce using existing infrastructure will see this little company as a gem and its technology as something they can apply in many more directions. There are just too many aspects of CEMI 's tech for it to remain under appreciated.
Also a reminder..we've been solidly above that $5 line for over a month and pretty consistent even for 3 months , so there may be some fund buying going on here that wasn't there before. Some of the small cap health or other small cap funds are able to take a position now that $5 line is crossed.
Sentiment: Strong Buy
Another approach might be to expand just a bit more finding 8 or so long term diversified core holdings, and then another 4-6 where you have increasingly higher risk. I have enough funds and accounts where I do this multiple times, so in retirement my cores tend to also pay a bit of a divi (although not all) and then I have a few where I am looking for some good growth and maybe a swing for the fences with about 5-10% of the $$ (1or 2 holdings). Its worked well. I can trim back here and there and I evaluate the core holdings sort of monthly or with significant news. With the swings I feel protected and I try to never loose more than 30%. I do average in with some picks. I've been at this as a personal investor and investor for several family members for about 3 decades and it works pretty well.
Bought my 10K at $9.35 sold 2000 at $24 in retirement so tax free, the rest is waiting for news other than general oil prices. It happens, hit and take some profit while waiting for more. You may want to run to lunch I want to retire and travel a bit.
noted. I don't post much. and too old to take stranger insults to heart. There are so many styles to investing and I think each person needs to be comfortable in his or her space. I've helped some younger investors and I'm a kind person and see no point in hurling (pun intended) insults. thanks for the warning!
Sorry, no #$%$ here. See if you can figure out a vulgar reply to a woman if you must. I am not arrogant. I try to be disciplined and academic in the way I invest and although I have no specific business education, I have taken the time to learn as much as I can to help my methods work for me and they do. I think charting is cool, and it has its uses, but with biotechs understanding the science, reading clinical trials and journal results, knowing the needs of the medical community (how many people are we/can we/ might we treat) is more sensible. If that's arrogance in your book, my guess is you are likely under 30 and a guy who hasn't quite figured out a mature approach to many things.
Its good to have discipline, and 15% (or basically money you can afford to loose or lose half of - that was my rule-is a good percent). My portfolio fluctuates in percent now since some have hit it pretty big and so I can be as high as 40% depending on trimming and holding, and enough different companies so if one or 2 completely blow up my lifestyle doesn't change.
Yes, well then use that to make buy and sell decisions if you must. I just stick to my rule of trying to pick the best, watch and read carefully, hopefully take my initial investment off the table sometime in the first 2-3 years, and let the rest run for the roses. I started a trust for 2 kids when they were 1 and 3 with 25K, and mostly by investing in biotech and a few core holdings sent both to $50K year colleges (7 years total- my son graduated in 3) with enough leftover to pay his part time grad school tuition (MS next month), and part of his down payment on a house in CA and sending my daughter to grad school full time 2 years (she has another year) and they are both loan and debt free. You do the math. My microbio back ground and 15 years in healthcare help along with investing since I was 15. I'm not a chartist or a market timer..average in average out watch taxes etc.
After years and years of biotech investing, and even after they pass the $5 mark, technicals are fun for people who like to follow them, but the stock price really responds some to biotech market sentiment and even more to actual news specific to clinical trials, FDA approvals, and direct competition. You can look for arbitrary resistance levels and support levels for the trader game - not for the long term investor who sees this particular company for the products it will bring to market, the partnerships it forms, and the applications of its research, and ability to capture market share. Products that compliment and enhance the value of treatments on the market will always be quickly adopted by practitioners, and small companies with products that compliment, supplement, or in some other way enhance products being used are often candidates for acquisition. So, if your trading for pennies, then chart away, but if you are trying to retire and create a substantial nest egg, read, invest, read more, and be patient.
Sentiment: Strong Buy